Oncology · Clinical trials
Osteosarcoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About osteosarcoma — and why its trials are hard
Osteosarcoma is the most common primary malignant bone tumour, arising chiefly in the metaphyses of long bones in adolescents and young adults, with a second peak in older adults. Cure depends on multi-agent chemotherapy combined with aggressive surgical resection. The MAP regimen (high-dose methotrexate, doxorubicin/Adriamycin and cisplatin) has been the global standard of care since the 1980s, curing roughly 60-70% of patients with localised disease but far fewer with metastatic or relapsed disease, where survival remains poor. Strikingly, no genuinely new systemic agent has meaningfully improved frontline cure rates in over three decades, making osteosarcoma a paradigm of stalled therapeutic progress. Mifamurtide is approved in Europe as an immunostimulant adjunct to chemotherapy but was not approved by the FDA. Development is hampered by rarity, marked genomic complexity and instability (rather than a single targetable driver), and the ethical and logistical difficulty of trials in children. Multi-kinase inhibitors such as regorafenib and cabozantinib show activity in relapsed disease but are not curative, leaving substantial unmet need.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| MAP chemotherapy (methotrexate, doxorubicin, cisplatin) (generic combination) | 1980s (established standard) | Neoadjuvant and adjuvant treatment of resectable high-grade osteosarcoma | Cooperative-group studies; EURAMOS-1 confirmed as backbone | Event-free and overall survival | ~60-70% long-term survival in localised disease; substantially lower if metastatic |
| Mifamurtide (L-MTP-PE) (Mepact) | 2009 (EU; not FDA-approved) | Adjunct to postoperative chemotherapy in non-metastatic resectable osteosarcoma | INT-0133 (phase 3) | Overall survival | Addition improved 6-year OS (~78% vs 70%); FDA declined approval citing design concerns |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in osteosarcoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ifosfamide/etoposide intensification (MAPIE) — EURAMOS-1 | Adding ifosfamide + etoposide for poor histologic responders did not improve event-free survival and increased toxicity | Response-adapted intensification hypothesis not borne out; added regimen-related toxicity without survival benefit |
| Pegylated interferon alfa-2b — EURAMOS-1 (good-responder maintenance) | Maintenance pegIFN after MAP showed no significant EFS improvement; poor tolerability and adherence | Modest immunologic rationale; substantial discontinuation limited any potential effect |
| Denosumab / trastuzumab and other targeted agents — Various early-phase / COG studies | Repeated failures of targeted and antibody approaches to translate into cure; no frontline approvals | Genomic complexity and instability rather than a single actionable driver; small heterogeneous populations |
Choosing the right endpoint
Primary endpoints that matter in osteosarcoma trials
- Event-free survival (EFS) — Primary frontline endpoint capturing relapse, progression, second malignancy or death; used in EURAMOS-1
- Overall survival (OS) — Ultimate measure of cure; historically static for three decades despite regimen modifications
- Histologic response to neoadjuvant chemotherapy — Percent tumour necrosis at resection is a strong prognostic marker (>=90% necrosis favourable) but has not proven useful as a treatment-switching guide
- Limb-salvage / local control rate — Surgical outcome reflecting successful downstaging and resection with function preservation
- Progression-free survival (PFS) — Endpoint in relapsed/refractory trials of multikinase inhibitors (e.g., regorafenib) where cure is not expected
How iNGENū runs osteosarcoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Osteosarcoma clinical trials — FAQs
Why hasn't treatment improved in over 30 years?
Is mifamurtide available everywhere?
What are the options when osteosarcoma relapses?
Ready to discuss your osteosarcoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal